(Q43765049)

26 November 2017

title

Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. (English)

1 reference

chronic obstructive pulmonary disease

26 November 2017

main subject

1 reference

Donald P Tashkin

1

1 reference

26 November 2017

James Pearle

series ordinal

2

1 reference

26 November 2017

Domenic Iezzoni

series ordinal

3

1 reference

26 November 2017

Santosh T Varghese

series ordinal

4

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 February 2009

1 reference

COPD: Journal of Chronic Obstructive Pulmonary Disease

26 November 2017

published in

1 reference

26 November 2017

volume

6

1 reference

26 November 2017

issue

1

1 reference

26 November 2017

page(s)

17-25

1 reference

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F15412550902724073

A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550902724073

Long-term Treatment Benefits With Tiotropium in COPD Patients With and Without Short-term Bronchodilator Responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550902724073

Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550902724073

Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550902724073

Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550902724073

The role of long-acting bronchodilators in the management of stable COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550902724073

Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550902724073

Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550902724073

Challenges and opportunities for combination therapy in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550902724073

The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550902724073

Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550902724073

Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550902724073

Minimal clinically important differences in COPD lung function

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550902724073

Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550902724073

Incremental Benefit of Adding Oxitropium Bromide to Formoterol in Patients with Stable COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550902724073

10.1080/15412550902724073

21 January 2018

Identifiers

DOI

1 reference

26 November 2017

1 reference